Imatinib Induced Delayed and Refractory Generalized Fluid Retention: A Case Report and Review of Literature
| Autor: | Yaser Gad, Fayez G Alruwaily, Bader A. Abdelmaksoud |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
biology
CD117 business.industry medicine.drug_class medicine.medical_treatment Imatinib General Medicine Tyrosine-kinase inhibitor Targeted therapy Refractory hemic and lymphatic diseases Toxicity Ascites biology.protein Cancer research Medicine Phosphorylation medicine.symptom business neoplasms medicine.drug |
| Zdroj: | Biomedical Journal of Scientific & Technical Research. 19 |
| ISSN: | 2574-1241 |
| DOI: | 10.26717/bjstr.2019.19.003233 |
| Popis: | The molecular targeted therapy started with introduction of tyrosine kinase inhibitor (Imatinib) that selectively inhibit phosphorylation of BCR-ABL protein with subsequent inhibition of growth of BCR-ABL positive cells [1]. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|